Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
S095029 · 1 trial · 2 indications
Phase 1b and Phase 2
Phase 1b and Phase 2
Phase 1b and Phase 2
Phase 1b and Phase 2
Phase 2 ONLY. The Proportion of participants who achieve complete response (CR) or partial response (PR), as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
| Arm | Type | Description |
|---|---|---|
| S095029 and pembrolizumab | EXPERIMENTAL | Participants diagnosed with gastric cancer (GC) or gastroesophageal junction cancer (GEJ), not previously treated with checkpoint inhibitors (CPIs) may first be enrolled into a Phase 1b safety lead-in part which will be used to identify the recommended Phase 2 dose (RP2D) of S095029 in combination with pembrolizumab. During the Phase 2 part, participants will receive the recommended Phase 2 dose (RP2D) of S095029, along with pembrolizumab. |
| Name | Type | Description |
|---|---|---|
| S095029 | DRUG | Participants will be treated with S095029 via intravenous (IV) infusion every 3 weeks (Q3W). |
| pembrolizumab 200 mg (KEYTRUDA ®) | DRUG | Participants will be treated with 200 mg of pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W). |
Inclusion Criteria: * Have a confirmed diagnosis of locally advanced and unresectable or metastatic gastric or gastro-esophageal junction adenocarcinoma * Participants' tumor must have an MSI-H/dMMR status according to institutional guidelines and/or according to the College of American Pathologist...
S095029 is an investigational small molecule being studied for the treatment of MSI-H/dMMR gastroesophageal-junction cancer and MSI-H/dMMR gastric cancer. It is currently in Phase 1 clinical development as part of a combination therapy for advanced gastroesophageal junction and gastric cancers.
S095029 is being developed by Tango Therapeutics, Inc. (NASDAQ: TNGX). The company is conducting a Phase 1 clinical trial to evaluate the safety and activity of S095029 as part of combination therapy in advanced gastroesophageal junction and gastric cancers.
S095029 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is active but not recruiting participants, with a planned enrollment of 48 patients.
S095029 is being evaluated in a single Phase 1 clinical trial, NCT06116136, titled "A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers." The trial is active but not recruiting and is enrolling patients with MSI-H/dMMR gastroesophageal-junction or gastric cancer.
No alternative names for S095029 have been disclosed. The drug is identified solely by its code name S095029 in clinical trial records and is being developed by Tango Therapeutics for the treatment of MSI-H/dMMR gastroesophageal-junction and gastric cancers.